> Details

Shkodra, Blerina; Kretzer, Christian; Jordan, Paul M.; Klemm, Paul; Koeberle, Andreas; Pretzel, David; Banoglu, Erden; Lorkowski, Stefan; Wallert, Maria; Höppener, Stephanie; Stumpf, Steffi; Vollrath, Antje; Schubert, Stephanie; Werz, Oliver; Schubert, Ulrich S.

Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Encapsulation of the dual FLAP/mPEGS-1 inhibitor BRP-187 into acetalated dextran and PLGA nanoparticles improves its cellular bioactivity
  • Contributor: Shkodra, Blerina; Kretzer, Christian; Jordan, Paul M.; Klemm, Paul; Koeberle, Andreas; Pretzel, David; Banoglu, Erden; Lorkowski, Stefan; Wallert, Maria; Höppener, Stephanie; Stumpf, Steffi; Vollrath, Antje; Schubert, Stephanie; Werz, Oliver; Schubert, Ulrich S.
  • Published: Springer Science and Business Media LLC, 2020
  • Published in: Journal of Nanobiotechnology, 18 (2020) 1
  • Language: English
  • DOI: 10.1186/s12951-020-00620-7
  • ISSN: 1477-3155
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Dual inhibitors of the 5-lipoxygenase-activating protein (FLAP) and the microsomal prostaglandin E<jats:sub>2</jats:sub> synthase-1 (mPGES-1) may exert better anti-inflammatory efficacy and lower risks of adverse effects versus non-steroidal anti-inflammatory drugs. Despite these advantages, many dual FLAP/mPGES-1 inhibitors are acidic lipophilic molecules with low solubility and strong tendency for plasma protein binding that limit their bioavailability and bioactivity. Here, we present the encapsulation of the dual FLAP/mPGES-1 inhibitor BRP-187 into the biocompatible polymers acetalated dextran (Acdex) and poly(lactic-<jats:italic>co</jats:italic>-glycolic acid) (PLGA) via nanoprecipitation.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The nanoparticles containing BRP-187 were prepared by the nanoprecipitation method and analyzed by dynamic light scattering regarding their hydrodynamic diameter, by scanning electron microscopy for morphology properties, and by UV–VIS spectroscopy for determination of the encapsulation efficiency of the drug. Moreover, we designed fluorescent BRP-187 particles, which showed high cellular uptake by leukocytes, as analyzed by flow cytometry. Finally, BRP-187 nanoparticles were tested in human polymorphonuclear leukocytes and macrophages to determine drug uptake, cytotoxicity, and efficiency to inhibit FLAP and mPGES-1.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Our results demonstrate that encapsulation of BRP-187 into Acdex and PLGA is feasible, and both PLGA- and Acdex-based particles loaded with BRP-187 are more efficient in suppressing 5-lipoxygenase product formation and prostaglandin E<jats:sub>2</jats:sub> biosynthesis in intact cells as compared to the free compound, particularly after prolonged preincubation periods.</jats:p> </jats:sec><jats:sec> <jats:title>Graphical Abstract</jats:title> </jats:sec>
  • Access State: Open Access